FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892365509> ?p ?o ?g. }

• W2892365509 abstract "Background CR6086 is a novel PGE2 EP4 receptor antagonist showing favourable immunomodulatory properties, striking DMARD effects in rodents, and an anti-inflammatory activity targeted to immune-mediated diseases and distinct from that of NSAIDs. Besides its role in controlling T cells, PGE2 is implicated in the aggressive bone erosion of rheumatoid arthritis (RA). Objectives To characterise CR6086 activity on the bone compartment mostly affected by erosion in the CIA model in rats. Methods 15 male Lewis rats were immunised by intradermal injection with collagen II in CFA. 5 naive animals were the sham group. 3 days after boost, oedema was assessed and rats assigned to treatment with vehicle or CR6086 (3 or 10 mg/kg qd). Oedema was measured again on days 7 and 14, and hindlimb joints were blindly scored for clinical signs of arthritis (scale 0–4; from normal=0 to maximally inflamed limb with involvement of multiple joints=4). At sacrifice, hindlimb calcaneus underwent high-resolution X-ray microCT (total and cancellous bone), a sensitive method that allows the reduction of experimental animals in compliance with the 3R rule. Parameters were expressed as the mean of left and right paw. Joints were then scored for histological features. Statistics were performed by ANOVA, correlations by Spearman analysis. Results CR6086 significantly reduced bone loss in CIA rats (table 1), even at the low dose of 3 mg/kg. The effect on cancellous bone plateaued already at 3 mg/kg, confirming the sensitivity of the metabolically more active districts of bone to the action of EP4 antagonists. There was a strict correlation between clinical score and bone parameters (BMD; figure 1 inset), confirming that bone erosion in CIA is closely associated with arthritis severity. Conclusions CR6086 is an EP4 antagonist in clinical development for RA (NCT03163966). Besides its immunomodulatory activity, CR6086 effectively decreases the aggressive bone erosion that characterises both the CIA model and the early phases of human RA. Disclosure of Interest M. Lanza Employee of: Rottapharm Biotech, G. Caselli Employee of: Rottapharm Biotech, F. Ferrari Employee of: Rottapharm Biotech, A. Grotti Employee of: Rottapharm Biotech, R. Cavagnoli Employee of: Rottapharm Biotech, M. Perrella: None declared, F. Daubine Employee of: Atlantic Bone Screen, V. Ayer Employee of: Rottapharm Biotech, L. Rovati Employee of: Rottapharm Biotech" @default.
• W2892365509 created "2018-09-27" @default.
• W2892365509 creator A5012772103 @default.
• W2892365509 creator A5025549282 @default.
• W2892365509 creator A5035229654 @default.
• W2892365509 creator A5047692961 @default.
• W2892365509 creator A5059093629 @default.
• W2892365509 creator A5063288145 @default.
• W2892365509 creator A5081464545 @default.
• W2892365509 creator A5087089921 @default.
• W2892365509 creator A5089473950 @default.
• W2892365509 date "2018-06-01" @default.
• W2892365509 modified "2023-10-04" @default.
• W2892365509 title "THU0085 Cr6086, a novel ep4 antagonist with immunomodulatory properties, decreases bone loss in the rat collagen-induced arthritis (CIA) model: a microtomography (MICROCT) study" @default.
• W2892365509 doi "https://doi.org/10.1136/annrheumdis-2018-eular.2402" @default.
• W2892365509 hasPublicationYear "2018" @default.
• W2892365509 type Work @default.
• W2892365509 sameAs 2892365509 @default.
• W2892365509 citedByCount "1" @default.
• W2892365509 countsByYear W28923655092021 @default.
• W2892365509 crossrefType "proceedings-article" @default.
• W2892365509 hasAuthorship W2892365509A5012772103 @default.
• W2892365509 hasAuthorship W2892365509A5025549282 @default.
• W2892365509 hasAuthorship W2892365509A5035229654 @default.
• W2892365509 hasAuthorship W2892365509A5047692961 @default.
• W2892365509 hasAuthorship W2892365509A5059093629 @default.
• W2892365509 hasAuthorship W2892365509A5063288145 @default.
• W2892365509 hasAuthorship W2892365509A5081464545 @default.
• W2892365509 hasAuthorship W2892365509A5087089921 @default.
• W2892365509 hasAuthorship W2892365509A5089473950 @default.
• W2892365509 hasBestOaLocation W28923655091 @default.
• W2892365509 hasConcept C126322002 @default.
• W2892365509 hasConcept C170493617 @default.
• W2892365509 hasConcept C2776885963 @default.
• W2892365509 hasConcept C2777077863 @default.
• W2892365509 hasConcept C2778844214 @default.
• W2892365509 hasConcept C71924100 @default.
• W2892365509 hasConceptScore W2892365509C126322002 @default.
• W2892365509 hasConceptScore W2892365509C170493617 @default.
• W2892365509 hasConceptScore W2892365509C2776885963 @default.
• W2892365509 hasConceptScore W2892365509C2777077863 @default.
• W2892365509 hasConceptScore W2892365509C2778844214 @default.
• W2892365509 hasConceptScore W2892365509C71924100 @default.
• W2892365509 hasLocation W28923655091 @default.
• W2892365509 hasOpenAccess W2892365509 @default.
• W2892365509 hasPrimaryLocation W28923655091 @default.
• W2892365509 hasRelatedWork W1976714598 @default.
• W2892365509 hasRelatedWork W2027055909 @default.
• W2892365509 hasRelatedWork W2035312173 @default.
• W2892365509 hasRelatedWork W2115361011 @default.
• W2892365509 hasRelatedWork W2352289998 @default.
• W2892365509 hasRelatedWork W2379622864 @default.
• W2892365509 hasRelatedWork W2414271022 @default.
• W2892365509 hasRelatedWork W2913883964 @default.
• W2892365509 hasRelatedWork W3109605373 @default.
• W2892365509 hasRelatedWork W4299530039 @default.
• W2892365509 isParatext "false" @default.
• W2892365509 isRetracted "false" @default.
• W2892365509 magId "2892365509" @default.
• W2892365509 workType "article" @default.